Afatinib
  
Side effects 
	
		
Options: 
			
			Show MedDRA Preferred Terms
		
	
	
| Side effect | Data for drug | Placebo | Labels | 
|  | 1 | 2 | 
| Dermatitis acneiform | very common, 0% - 90% |  | x | x | 
| Diarrhoea | very common, 0% - 96% |  | x | x | 
| Rash | very common, 0% - 90% |  | x | x | 
| Paronychia | very common, 0% - 58% |  | x | x | 
| Stomatitis | very common, 0% - 71% |  | x | x | 
| Decreased appetite | very common, 0% - 29% |  | x | x | 
| Epistaxis | very common, 0% - 17% |  | x | x | 
| Pruritus | very common, 0% - 21% |  | x | x | 
| Dry skin | very common, 0% - 31% |  | x | x | 
| Dehydration | common |  |  | x | 
| Dysgeusia | common |  |  | x | 
| Dyspepsia | common |  |  | x | 
| Renal failure | common |  |  | x | 
| Muscle spasms | common |  |  | x | 
| Aspartate aminotransferase increased | common, 2% - 8% |  | x | x | 
| Dry eye | common |  |  | x | 
| Renal impairment | common |  |  | x | 
| Hypokalaemia | common, 2% - 11% |  | x | x | 
| Vomiting | 0% - 23% |  | x | x | 
| Alanine aminotransferase increased | common, 0% - 11% |  | x | x | 
| Cystitis | common, 0% - 13% |  | x | x | 
| Weight decreased | common, 0% - 17% |  | x | x | 
| Cheilitis | common, 0% - 12% |  | x | x | 
| Conjunctivitis | common, 0% - 11% |  | x | x | 
| Body temperature increased | common, 0% - 12% |  | x | x | 
| Rhinorrhoea | common, 0% - 11% |  | x | x | 
| Fatigue | 0% - 19% |  | x | x | 
| Nausea | 0% - 25% |  |  | x | 
| Keratitis | uncommon |  | x | x | 
| Interstitial lung disease | uncommon |  | x | x | 
| Pneumonia | 0.43% |  | x |  | 
| Sepsis | 0.43% |  | x |  | 
| Alopecia | 0% - 13% |  |  | x | 
| Back pain | 0% - 14% |  |  | x | 
| Mental disorder |  |  |  | x | 
| Infection |  |  | x | x | 
| Connective tissue disorder |  |  |  | x | 
| Constipation | 0% - 13% |  |  | x | 
| Cough | 0% - 15% |  |  | x | 
| Dizziness | 0% - 11% |  |  | x | 
| Dyspnoea |  |  | x |  | 
| Eye disorder |  |  | x | x | 
| Gastrointestinal disorder |  |  | x | x | 
| Headache | 0% - 14% |  |  | x | 
| Mediastinal disorder |  |  | x | x | 
| Nasopharyngitis | 0% - 14% |  |  | x | 
| Nervous system disorder |  |  |  | x | 
| Skin disorder |  |  | x |  | 
| Aphthous stomatitis |  |  |  | x | 
| Upper respiratory tract infection | 0% - 11% |  |  | x | 
| Urinary tract infection |  |  |  | x | 
| Urinary tract disorder |  |  |  | x | 
| Mouth ulceration |  |  |  | x | 
| Malnutrition |  |  | x | x | 
| Unspecified disorder of skin and subcutaneous tissue |  |  | x | x | 
| Mucosal ulceration |  |  |  | x | 
| Conjunctival irritation |  |  |  | x | 
| Disease progression |  |  | x |  | 
| Left ventricular dysfunction |  |  | x |  | 
| Ventricular dysfunction |  |  | x |  | 
| Acne pustular |  |  |  | x | 
| Hepatobiliary disease |  |  |  | x | 
| Mucosal inflammation |  |  |  | x | 
| Nail infection |  |  |  | x | 
| Oral mucosa erosion |  |  |  | x | 
| Pruritus generalised |  |  |  | x | 
| Diastolic dysfunction |  |  | x |  | 
| Nail bed infection |  |  |  | x | 
| Mucosal erosion |  |  |  | x | 
| Chapped skin |  |  |  | x | 
| Infestation NOS |  |  | x | x | 
| Blood potassium decreased |  |  |  | x | 
| Insomnia | 0% - 15% |  |  | x | 
| Pulmonary toxicity |  |  | x |  | 
| Conjunctival hyperaemia |  |  |  | x | 
| Nasal inflammation |  |  |  | x | 
	 
 
  Indications
	Information about indications was extracted from the indications and usage sections of the labels.
	
 
	  
	  
		| Side effects: | 38 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 67 | 
|---|
		| Source: | medicines.org.au | 
|---|
		 
	  
  
 
  
	Color scheme:
	  
	  standard – alternative
	  
	
	
|  |  | 100% | 
|  |  | 75% | 
|  |  | 50% | 
|  |  | 10% | 
|  |  | frequent (1% to 100%) | 
|  |  | infrequent (0.1% to 1%) | 
|  |  | rare (<0.1%) | 
|  |  | postmarketing | 
|  |  | 0% | 
|  |  | no frequency information | 
|  |  | not found on label |